In conclusion, our data demonstrate that selective inhibition of HDAC1/2 by ACY-957 induces HBG and HbF, providing a foundation for in vivo animal studies and further development of ACY-957 as a therapy for SCD and β-thalassemia. Here, HDAC1 is linked to Schnyder corneal dystrophy.